Value Play Or Value Trap? NiSource Inc. (NI), Bristol-Myers Squibb Company (BMY)

6 analysts out of 13 Wall Street brokerage firms rate NiSource Inc. (NYSE:NI) as a Buy, while 0 see it as a Sell. The rest 7 describe it as a Hold. NI stock traded higher to an intra-day high of $28.72. At one point in session, its potential discontinued and the price was down to lows at $28.385. Analysts have set NI’s consensus price at $28.91, effectively giving it a 1.51% projection on returns. Should the projected estimates be met, then the stock will likely hit its highest price at $32 (up 12.36% from current price levels). NI has a -2.8% ROE, lower than the 13.66% average for the industry. The average ROE for the sector is 11.86%.

NiSource Inc. (NI) currently trades at $28.48, which is lower by -0.18% its previous price. It has a total of 374.15 million outstanding shares, with an ATR of around 0.41. The company’s stock volume dropped to 2.57 million, worse than 2.69 million that represents its 50-day average. A 5-day decrease of about -0.49% in its price means NI is now 12.35% higher on year-to-date. The shares have surrendered $43237.52 since its $28.89 52-week high price recorded on 7th of June 2019. Overall, it has seen a growth rate of 20.02 over the last 12 months. The current price per share is $4.83 above the 52 week low of $23.65 set on 15th of June 2018.

NiSource Inc. (NYSE:NI)’s EPS was $0.82 as reported for the March quarter. In comparison, the same quarter a year ago had an EPS of $0.77. That means that its growth in general now stands at 6%. Therefore, a prediction of $0.77 given by the analysts brought a positive surprise of 6%. NI March quarter revenue was $1.87 billion, compared to $1.75 billion recorded in same quarter last year, giving it a 7% growth rate. The company’s $0.12 billion revenue growth that quarter surprised Wall Street and investors will need to consider this as they assess the stock.

Bristol-Myers Squibb Company (NYSE:BMY) shares depreciated -0.63% over the last trading period, taking overall 5-day performance up to 2.56%. BMY’s price now at $47.33 is greater than the 50-day average of $46.47. Getting the trading period increased to 200 days, the stock price was seen at $51.54 on average. The general public currently hold control of a total of 1.63 billion shares, which is the number publicly available for trading. The total of shares that it has issued to investors is 1.63 billion. The company’s management holds a total of 0.1%, while institutional investors hold about 80.1% of the remaining shares. BMY share price finished last trade 1.62% above its 20 day simple moving average and its downbeat gap from 200 day simple moving average is -8.27%, while closing the session with 1.88% distance from 50 day simple moving average.

Bristol-Myers Squibb Company (BMY) shares were last observed trading -25.69% down since October 09, 2018 when the peak of $63.69 was hit. Last month’s price growth of 3.09% puts BMY performance for the year now at -8.95%. Consequently, the shares price is trending higher by 6.84%, a 52-week worst price since Jan. 03, 2019. However, it is losing value with -9.73% in the last 6 months. From a technical perspective, it appears more likely that the stock will experience a Bull Run market as a result of the strong support seen recently between $46.58 and $46.95. The immediate resistance area is now $47.72 Williams’s %R (14) for BMY moved to 14.12 while the stochastic %K points at 84.24.

BMY’s beta is 0.73; meaning investors could reap lower returns, although it also poses lower risks. The company allocated $3.16 per share from its yearly profit to its outstanding shares. Its last reported revenue is $5.92 billion, which was 14% versus $5.19 billion in the corresponding quarter last year. The EPS for Mar 19 quarter came in at $1.1 compared to $0.94 in the year-ago quarter and had represented 17% year-over-year earnings per share growth. BMY’s ROA is 15.1%, higher than the 9.99% industry average. Although a more robust percentage would be better, consideration is given to how well peers within the industry performed. Companies within the sector had an ROA of 9.63%.

Estimated quarterly earnings for Bristol-Myers Squibb Company (NYSE:BMY) are around $1.03 per share in three months through June with $1.03 also the estimate for September quarter of the fiscal year. It means the growth is estimated at 1.98% and -5.5%, respectively. Analysts estimate full-year growth to be 5.03%, the target being $4.18 a share. The upcoming year will see an increase in growth by percentage to 20.33%, more likely to see it hit the $5.03 per share. The firm’s current profit margin over the past 12 months is 22.1%. BMY ranks higher in comparison to an average of -7.19% for industry peers; while the average for the sector is -12.05%.